Artwork

Indhold leveret af Cambridge Healthtech Institute. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af Cambridge Healthtech Institute eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.
Player FM - Podcast-app
Gå offline med appen Player FM !

Episode: 66 - John Lambert on Antibody Drug Conjugates Then, Now, & Beyond

39:43
 
Del
 

Manage episode 445443266 series 2967424
Indhold leveret af Cambridge Healthtech Institute. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af Cambridge Healthtech Institute eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

October 15, 2024 | In this month’s episode of The Chain, host Rakesh Dixit, PhD, DABT, president and founder of Bionavigen Oncology and Regio Biosciences, and John Lambert, PhD, consultant, about antibody drug conjugates (ADCs) then, now, and beyond. Lambert shares his experiences from his decades-long career at ImmunoGen, why ADCs are more successful now compared to in the past, and where he sees ADCs going forward. He also discusses his thoughts on the half-life of diffusible payloads, the toxicity of the bystander effect, and more.
LINKS:
Bionavigen
ImmunoGen

  continue reading

71 episoder

Artwork
iconDel
 
Manage episode 445443266 series 2967424
Indhold leveret af Cambridge Healthtech Institute. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af Cambridge Healthtech Institute eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.

October 15, 2024 | In this month’s episode of The Chain, host Rakesh Dixit, PhD, DABT, president and founder of Bionavigen Oncology and Regio Biosciences, and John Lambert, PhD, consultant, about antibody drug conjugates (ADCs) then, now, and beyond. Lambert shares his experiences from his decades-long career at ImmunoGen, why ADCs are more successful now compared to in the past, and where he sees ADCs going forward. He also discusses his thoughts on the half-life of diffusible payloads, the toxicity of the bystander effect, and more.
LINKS:
Bionavigen
ImmunoGen

  continue reading

71 episoder

Alle episoder

×
 
Loading …

Velkommen til Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Hurtig referencevejledning

Lyt til dette show, mens du udforsker
Afspil